- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | Apr 3, 2024
Deals
With $1.8B ProfoundBio deal, Genmab gains chance to market ‘100% owned’ product
Along with ADC platform, the Danish antibody specialist gains a FOLR1-targeting product entering pivotal testing for ovarian cancer
BioCentury | Jun 18, 2021
Deals
BMS adds new mechanism to solid tumor pipeline via ADC deal with Eisai
BMS-Eisai collaboration follows an active year in ADC dealmaking
BioCentury | Oct 28, 2020
Product Development
Data Byte: FOLR1 pipeline for cancer
At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.
BioCentury | Oct 27, 2017
Company News
Fujirebio developing companion diagnostic for Morphotek's farletuzumab
Items per page:
1 - 10 of 24